RxDoctor Payments Data

Stephanie McKay

Psychiatric/Mental Health · Wilmington, DENPI 1710603865

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 291 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,133in general payments, 2019–2025

Across 291 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$736
  • Alkermes, Inc.$592
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$555
  • Axsome Therapeutics, Inc.$537
  • Lundbeck LLC$489
  • Otsuka America Pharmaceutical, Inc.$479
  • plus $3K from 20 others

What the payments were for

  • Food & beverage$6,133100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,133 in reported general payments places this provider in the 95th percentile of 177 psychiatric/mental health providers in Delaware.

See all psychiatric/mental health providers in Delaware

Medicare billing

Part B allowed, 2024
$7,200
Medicare patients
11
Services billed
91

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Methylphenidate ErMethylphenidate Hcl11$488
Clonazepam26$235
Trazodone Hcl11$79

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →